Scholarlink

Purpose <p>To investigate the relationship between baseline optical coherence tomography (OCT) features of wet age-related macular degeneration (wAMD) and prognosis, and evaluate anti-VEGF treatment effects under varying baseline OCT conditions.</p> Methods <p>This retrospective study included patients diagnosed with wAMD who underwent monthly anti-VEGF therapy for 1–3 months. Baseline, one-month, and three-month OCTs recorded morphological features. Treatment effectiveness was defined as central retinal thickness (CRT) reduction ≥ 25%, or absence of subretinal fluid (SRF) and intraretinal fluids (IRF) post-treatment.</p> Results <p>Data from 251 eyes were analyzed. After one injection, effective responders had smaller baseline lesion sizes (11.01 ± 9.93 vs. 12.53 ± 8.80, <i>P</i> = 0.046), lower PED height (124.10 ± 232.55 vs. 216.06 ± 248.66, <i>P</i> &lt; 0.001), and larger baseline IRF (86.52 ± 154.74 vs. 31.26 ± 81.14, <i>P</i> = 0.002) compared to non-responders. After three injections, effective responders continued to show larger baseline IRF (65.94 ± 135.20 vs. 20.28 ± 61.93, <i>P</i> = 0.015). Multivariate analysis indicated greater CRT reductions at one and three months were associated with larger baseline CRT (<i>P</i> &lt; 0.001), larger baseline IRF (<i>P</i> &lt; 0.001 and <i>P</i> = 0.012), and absence of retinal hemorrhage (<i>P</i> = 0.003).</p> Conclusions <p>Baseline OCT features significantly influence treatment responsiveness in wAMD. Tailoring anti-VEGF regimens based on these features may improve outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Tengbo Rao,
  • Jiarui Yang,
  • Huijin Chen,
  • Xuemin Li

摘要

Purpose

To investigate the relationship between baseline optical coherence tomography (OCT) features of wet age-related macular degeneration (wAMD) and prognosis, and evaluate anti-VEGF treatment effects under varying baseline OCT conditions.

Methods

This retrospective study included patients diagnosed with wAMD who underwent monthly anti-VEGF therapy for 1–3 months. Baseline, one-month, and three-month OCTs recorded morphological features. Treatment effectiveness was defined as central retinal thickness (CRT) reduction ≥ 25%, or absence of subretinal fluid (SRF) and intraretinal fluids (IRF) post-treatment.

Results

Data from 251 eyes were analyzed. After one injection, effective responders had smaller baseline lesion sizes (11.01 ± 9.93 vs. 12.53 ± 8.80, P = 0.046), lower PED height (124.10 ± 232.55 vs. 216.06 ± 248.66, P < 0.001), and larger baseline IRF (86.52 ± 154.74 vs. 31.26 ± 81.14, P = 0.002) compared to non-responders. After three injections, effective responders continued to show larger baseline IRF (65.94 ± 135.20 vs. 20.28 ± 61.93, P = 0.015). Multivariate analysis indicated greater CRT reductions at one and three months were associated with larger baseline CRT (P < 0.001), larger baseline IRF (P < 0.001 and P = 0.012), and absence of retinal hemorrhage (P = 0.003).

Conclusions

Baseline OCT features significantly influence treatment responsiveness in wAMD. Tailoring anti-VEGF regimens based on these features may improve outcomes.